5th May Castillo-Mancilla et al., Incomplete ART adherence and cardiovascular events and mortality

Association of incomplete adherence to antiretroviral therapy with cardiovascular events and mortality in virologically suppressed persons with HIV: The Swiss HIV Cohort Study.    Open Forum Infectious Diseases

Castillo-Mancilla et al. aimed to assess the clinical implications of incomplete antiretroviral therapy (ART) adherence on the occurrence of cardiovascular events (CVD) and non-CVD-related death.

Persons with HIV (PWH) enrolled in the Swiss HIV Cohort Study without a history of CVD who initiated ART between 2003 and 2018 and had viral suppression (<50 copies/mL) for ≥6 months were evaluated for the association between incomplete self-reported ART adherence and (1) any CVD event (myocardial infarction, revascularization, cerebral hemorrhage, stroke, and/or death due to CVD event) or (2) non-CVD-related death. Incomplete ART adherence was defined as 1 or ≥2 self-reported missed doses in the last month.

A total of 6’971 PWH (74% male) were included in the analysis (median age [interquartile range {IQR}], 39 [32–47] years). The median (IQR) follow-up was 8 (4–11) years, with 14 (8–23) adherence questionnaires collected per participant. In total, 205 (3%) participants experienced a CVD event, and 186 (3%) died a non-CVD-related death. In an adjusted competing risk model where missing data were imputed, missing ≥1 ART dose showed an increased, but not statistically significant, risk for CVD events (hazard ratio [HR], 1.23; 95% CI, 0.85–1.79; P = .28). Non-CVD-related mortality showed a statistically significantly increased risk with missing ≥1 ART dose (HR, 1.44; 95% CI, 1.00–2.07; P = .05) and missing ≥2 ART doses (HR, 2.21; 95% CI, 1.37–3.57; P = .001).

In conclusion, the study demonstrated that incomplete (i.e., <100%) ART adherence is associated with an increased risk for non-CVD-related mortality in PWH who are virologically suppressed to <50 copies/mL. These findings suggest the potential critical role that ART adherence could have in improving clinical outcomes and open the door for further research on the role that increasing adherence - beyond suppression - could have in preventing morbidity/mortality in PWH who are considered optimally treated. Future studies to confirm this association and to understand its clinical implications are needed.


29th April Surial et al., Impact of binge drinking on mortality and liver disease

The impact of binge drinking on mortality and liver disease in the Swiss HIV Cohort Study.    Journal of Clinical Medicine

Surial et al. assessed whether binge drinking contributes to all-cause and liver-related mortality and to the occurrence of liver-related events among people living with HIV. Previous reports from the general population showed that individuals who reported binge drinking behaviour had a substantially increased risk of developing liver disease.

Based on the Alcohol Use Disorder Identification Test (AUDIT-C) score, time-varying alcohol drinking patterns were categorized into one of four groups: “abstinence”, “non-hazardous drinking”, “hazardous but not binge drinking”, and “binge drinking” (defined as ≥ 6 drinks/occasion at least monthly).

The study included 11’849 individuals with a median follow-up of 6.8 years. Overall, 470 individuals died, of whom 37 experienced a liver-related death, and 239 liver-related events occurred. Compared to individuals who reported non-hazardous drinking, those reporting binge drinking were more likely to die (adjusted incidence rate ratio [aIRR] 1.9, 95% CI 1.3-2.7 for all-cause mortality; aIRR 3.6, CI 0.9-13.9 for liver-related mortality) and to experience a liver-related event (aIRR 3.8, CI 2.4-5.8). Authors did not observe differences in outcomes between participants reporting non-hazardous and hazardous drinking without binge drinking.

In summary, this study shows that binge drinking is associated with an increased mortality and an increased risk for the development of liver disease among people living with HIV. Considering the high proportion of individuals who report harmful alcohol consumption and the high prevalence of liver disease in HIV cohorts, these patients may benefit from tailored risk reduction counselling.


22nd April Hovaguimian et al., Long-term risk of HIV infection in individuals seeking post-exposure prophylaxis

Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis.   Nature Communications

Hovaguimian et al. aimed to estimate the long-term risk of HIV infection in post-exposure prophylaxis (PEP-) seekers in a tertiary referral center. As previous evidence suggests that sexual risk taking occurs in phases lasting 12 to 24 months, they hypothesized that HIV infections would be clustered shortly after the time of PEP consultation.

Overall, there were 975 PEP-seekers between 2007 and 2013. Using privacy preserving probabilistic linkage, the authors linked these 975 records with two observational databases providing data on HIV events, the Zurich Primary HIV Infection study and the Swiss HIV Cohort Study, respectively. With this approach, they identified 22 HIV infections and obtained long-term follow-up data, which reveal a median of 4.1 years between consultation for post-exposure prophylaxis and HIV diagnosis. Even though men who have sex with men constituted only 35.8% of those seeking post-exposure prophylaxis, all 22 events occur in this subgroup.

In conclusion, in this retrospective data linkage study, the proportion of PEP seekers tested positive for HIV after PEP intake was 2.3%, and this proportion reached 6.3% in MSM. This study identified that most seroconversions occurred 4 years after PEP consultation, thereby bringing long-term insights into the risk of contracting HIV following PEP seeking. Those who seroconverted were all MSM, which should strongly encourage early consideration of PrEP in MSM after a first episode of PEP.


15th April Chammartin et al., non-AIDS-defining and AIDS-defining cancer and timing of ART initiation

Risk for non–AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy.    Annals of Internal Medicine

Chammartin et al. aimed to assess the impact of deferred and immediate start of antiretroviral therapy (ART) on the development of non-AIDS and AIDS-defining cancer.

Authors estimated the occurrence of cancer among participants from the D:A:D study and used causal inference methods to emulate a pragmatic trial comparing 3 treatment strategies: Immediate treatment irrespective of CD4 cell count, and treatment start at a CD4 cell count of less than 500 cells/µL or less than 350 cells/µL.

The study population included 8’318 individuals with a median age of 36 years (IQR 29–43), 77% were men, and the median CD4 cell count at baseline was 410 cells/µL (IQR 260–583). Over a median follow-up of 8.3 years, 231 persons developed non-AIDS defining (mainly Hodgkin lymphoma, lung, anal and prostate cancer) and 272 developed AIDS-defining cancer (Non-Hodgkin lymphoma, Kaposi sarcoma and cervical cancer). With immediate ART, the 10-year risk for AIDS-defining cancer was 2.50%, compared to 2.80% when treatment was started with a CD4 cell count below 500 cells/µL (difference to immediate treatment 0.32 percentage points, 95% CI 0.21–0.44), and 3.51% with a CD4 cell count below 350 cells/µL (difference 1.00 percentage points, CI 0.67–1.44). Differences in risk between the three strategies for the development of non-AIDS defining cancers were not statistically significant.

Taken together, this study shows that compared to a delayed ART start, immediate therapy leads to lower rates of AIDS-defining cancers. However, the risk reduction with immediate therapy is small and remains inconclusive for non-AIDS defining cancer. This is reassuring since almost half of patients currently start ART with a CD4 cell count below 500 cells/µL due to delayed diagnosis. Future research will need to better characterize the mechanisms behind the increased risk of cancer among people living with HIV compared with the general population.


8th April funding of the SHCS by the SNSF from 2021 to 2024 - thanks to all

Dear all,

We are very pleased to inform you that the SHCS will be funded with CHF 8,75 Mio from the Swiss National Science Foundation (SNSF) for the next 3,5 years (CHF 2,5 Mio/year). The reason we are still supported in these fast-moving times after 33 years is excellence in clinical care and outstanding research. There is a direct benefit from our work for patients but also for the society at large.

Therefore, we would like to thank first

  • all the patients participating in the SHCS

We also thank all of you who are working tireless for the SHCS

  • study nurses, physicians at the cohort centers and HIV-practitioners
  • technicians, FAMH physicians, virologists, microbiologists and immunologists taking care of the biobank
  • the data managers, the data center, the coordination center, all the administrative support we get at all levels
  • the Positivrat for actively participating in the SHCS Scientific Board
  • the many PhD, Postdocs, physician-scientists and master students who work in the research labs and in front of their computers analyzing all the data that is being generated on the many exciting research projects that are ongoing in the SHCS
  • all the national and international collaborators with whom the SHCS works together
  • the SNSF for funding, the SHCS research foundation
  • the Federal Office of Public Health for supporting public health initiatives of the SHCS
  • pharmaceutical companies
    • AbbVie, Gilead, MSD, ViiV for support of the SHCS research foundation by unrestricted grants to support the SHCS core projects
    • AbbVie, BMS, Gilead, Janssen, MSD, ViiV for the collaboration with the SHCS association
    • Some companies also support specific investigator initiated studies. We also thank you for this.

Thanks again for all your continuous support of the SHCS. We are looking forward to our further collaboration.

Best regards,

Huldrych Günthard Andri Rauch Marcel Stöckle
President of the SHCS Chairman of the
Scientific Board
Chairman of the Clinical
and Laboratory Board
31st March Surial and Mugglin et al., Metabolic changes after replacing TDF with TAF

Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV.    Annals of Internal Medicine.

Surial and Mugglin et al. evaluated the impact of switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir alafenamide (TAF) on weight, the development of obesity and other metabolic outcomes among participants on stable antiretroviral therapy.

Authors analyzed data from all individuals who received a TDF-containing therapy for 6 months or longer and compared weight trajectories and changes in lipid levels over 18 months between individuals who switched from TDF to TAF and those who continued TDF.

The study population included 4375 individuals; the median age was 50 years (IQR 43–56), 26% were women, and 52% had a normal body mass index. Overall, 3484 (79.6%) switched to TAF and 891 (20.4%) continued TDF. After 18 months, participants who switched to TAF experienced a mean weight increase of 1.7 kg (95% CI 1.5–2.0), compared with 0.7 kg (CI 0.4–1.0) with the continued use of TDF (between group difference 1.1 kg, CI 0.7–1.4). The difference between both groups was largest among women of African (1.5 kg) and non-African origin (1.4 kg), and among individuals who received integrase inhibitors (1.7 kg), but weight increases were greater with TAF than TDF with all third drugs used. Among individuals with a normal BMI, 13.8% who switched to TAF became overweight or obese, compared with 8.4% who remained on TDF. In a sensitivity analysis, patients who switched from abacavir (ABC)-containing regimens to TAF also experienced larger weight increases compared with those who continued ABC. Finally, the use of TAF was associated with greater increases in levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides compared with the continued use of TDF.

This study highlights that replacing TDF with TAF is associated with adverse metabolic changes, including weight increase, the development of obesity and worsening of blood lipid values. The increases in weight observed after switching from TDF and ABC to TAF further show that weight changes cannot only be explained by stopping TDF. Taken together, these findings underscore the need of a balanced evaluation of the advantages and potential harms when recommending TAF over TDF.


25th March Stader et al., Effect of ageing on antiretroviral drug pharmacokinetics

Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.    British Journal of Clinical Pharmacology

Stader et al. aimed to investigate age-related pharmacokinetic changes of HIV drugs by using a previously developed and verified physiologically based pharmacokinetic (PBPK) framework in combination with clinically observed data sampled as part of the Swiss HIV Cohort Study in ageing people living with HIV (PLWH).

Plasma concentrations for 10 first-line antiretrovirals were obtained in PLWH ≥55 years, participating in the Swiss HIV Cohort Study, and used to proof the predictive performance of the PBPK model. The verified PBPK model predicted the continuous effect of ageing on HIV drug pharmacokinetics across adulthood (20–99 years). The impact of ethnicity on age-related pharmacokinetic changes between whites and other races was statistically analyzed.

Clinically observed concentration-time profiles of all investigated antiretrovirals were generally within the 95% confidence interval of the PBPK simulations, demonstrating the predictive power of the modelling approach used. The predicted decline in drug clearance drove age-related pharmacokinetic changes of antiretrovirals, resulting in a maximal 70% [95% confidence interval: 40%, 120%] increase in antiretrovirals exposure across adulthood. Peak concentration, time to peak concentration and apparent volume of distribution were predicted to be unaltered by ageing. There was no statistically significant difference of age-related pharmacokinetic changes between studied ethnicities.

In conclusion, the impact of advanced ageing on antiretroviral drug pharmacokinetics is not clinically relevant considering the large therapeutic index of the current first-line treatment. In the current study, neither sex nor ethnicity appear to impact age-related pharmacokinetic changes. Overall, antiretroviral drug dose adjustment is a priori not necessary in ageing male and female PLWH in the absence of severe comorbidities.


12th March Roen et al., Health care index predicts TB-HIV mortality

A new health care index predicts short term mortality for TB and HIV co-infected people.    International Journal of Tuberculosis and Lung

Roen et al. aimed to re-evaluate a previously generated health care index (HCI) in a prospective cohort of tuberculosis (TB-) HIV co-infected individuals and to asses if additional factors, which parallel recent changes in TB-HIV health care management, predict mortality. They evaluated nine aspects of health care in Cox proportional hazards models on time from TB diagnosis to death.

Of 1’396 eligible individuals (72% male, 59% from Eastern Europe), 269 died within 12 months. Use of rifamycin/isoniazid/pyrazinamide based treatment (HR 0.67, 95% CI 0.50–0.89), TB drug susceptibility testing (DST) and number of active TB drugs (DST + <3 drugs (HR 1.09, 95% CI 0.80–1.48), DST + ≥3 drugs (HR 0.49, 95% CI 0.35–0.70) vs. no DST), recent HIV-RNA measurement (HR 0.64, 95% CI 0.50–0.82) and combination antiretroviral therapy use (HR 0.72, 95% CI 0.53–0.97) were associated with mortality. These factors contributed respectively 5, –1, 8, 5 and 4 to the HCI. Lower HCI was associated with an increased probability of death; 30% (95% CI 26–35) vs. 9% (95% CI 6–13) in the lowest vs. the highest quartile.

In conclusion, the authors improved their previous HCI to reflect recent changes in health care practices that predict 12-month mortality, even after adjusting for factors known to be associated with mortality among TB-HIV-positive individuals. The HCI has value in both high- and middle-income settings in Western and Eastern Europe, as well as Latin America. The proposed model suggests that five simple factors can be used to improve mortality among TB-HIV-positive individuals and to benchmark clinics and serve as a guide to improved health care provision to people with HIVTB.


4th March Thorball et al., Host genomics of the HIV-1 reservoir

Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment.    JAIDS

Thorball et al. aimed to assess host genetic factors associated with the HIV-1 reservoir size and its long-term dynamics in a cohort of 797 HIV-1 positive individuals on suppressive antiretroviral therapy (ART) for at least 5 years.

The authors measured total HIV-1 DNA in peripheral blood mononuclear cells from study participants, as a proxy for the reservoir size at 3 time points over a median of 5.4 years, and searched for associations between human genetic variation and 2 phenotypic readouts: the reservoir size at the first time point and its decay rate over the study period. They assessed the contribution of common genetic variants using genome-wide genotyping data from 797 patients with European ancestry enrolled in the Swiss HIV Cohort Study and searched for a potential impact of rare variants and exonic copy number variants using exome sequencing data generated in a subset of 194 study participants.

Based on their results, genome-wide and exome-wide analyses did not reveal any significant association with the size of the HIV-1 reservoir or its decay rate on suppressive antiretroviral treatment.

In conclusion, the study suggests that human individual germline genetic variation has little, if any, influence on the control of the HIV-1 viral reservoir size and its long-term dynamics. Complex, likely multifactorial biological processes govern HIV-1 viral persistence. Larger genomic studies, taking into account defined biological phenotypes and the differential biological importance of replication-competent and defective proviruses, will possibly clarify the role of common or rare genetic variants explaining small proportions of the variability of the phenotypes related to viral latency.


25th February Neesgaard et al., Outcomes of integrase inhibitors treatment

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.   PLoS One

Neesgaard et al. for The RESPOND study group aimed to compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-life setting.

Virologic and immunologic outcomes of INSTI use were compared to outcomes of PI/b or NNRTI treatment 12 months after treatment start or switch, for participants in the RESPOND cohort consortium. A composite treatment outcome (cTO) was used, defining success as viral load (VL) <200 copies/mL and failure as at least one of: ≥200 copies/mL, unknown VL in the time window, any changes of antiretroviral therapy (ART) regimen, AIDS, or death. In addition, on-treatment analysis including only individuals with known VL and no regimen changes was performed. Favorable immunologic response was defined as a 25% increase in CD4 count or as reaching ≥750 CD4 cells/μL.

Between January 2012 and January 2019, 13’703 (33.0% ART-naïve) individuals were included, of whom 7’147 started/switched to a regimen with an INSTI, 3’102 to a PI/b and 3’454 to an NNRTI-containing regimen. The main reason for cTO failure in all treatment groups were changes in ART regimen. Compared to INSTIs, the adjusted odds ratio (aOR) of cTO success was significantly lower for PI/b (0.74 [95% confidence interval, CI 0.67–0.82], p <0.001), but similar for NNRTIs (1.07 [CI 0.97–1.17], p = 0.11). On-treatment analysis and sensitivity analyses using a VL cut-off of 50 copies/mL were consistent. Compared to INSTIs, the aORs of a 25% increase in CD4 count were lower for NNRTIs (0.80 [CI 0.71–0.91], p<0.001) and PI/b (0.87 [CI 0.76–0.99], p = 0.04).

In conclusion, this large, real-world based analysis of a heterogeneous population of PLWH seen in routine clinical care showed that treatment with INSTI and NNRTI-containing regimes was preferable to PI/b with regard to virologic outcomes, although the potential for residual confounding cannot be fully excluded. Favorable immunologic responses were more likely with INSTI-containing regimens than with NNRTI-containing regimens, and to a lesser degree with PI/b-containing regimens. Crude numbers did not reveal any major differences in the occurrence of AIDS or death. These data supports the use of INSTI treatment and suggest that 12 months efficacy and durability of INSTIs are independent of prior treatment status and on-going viremia.


17th February Livio et al., Inappropriate prescribing in elderly people living with HIV

Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. Journal of Antimicrobial Chemotherapy

Livio et al. aimed to determine the prevalence of and risk factors for inappropriate prescribing in geriatric medicine among individuals aged ≥75 years enrolled in the Swiss HIV Cohort Study.

The authors did a retrospective review of medical records to gain more insights into non-HIV comorbidities. Inappropriate prescribing was screened using the Beers criteria, the STOPP/START criteria and the Liverpool drug–drug interactions (DDIs) database.

For 175 included individuals, the median age was 78 years (IQR 76–81) and 71% were male. The median number of non-HIV comorbidities was 7 (IQR 5–10). The prevalence of polypharmacy and inappropriate prescribing was 66% and 67%, respectively. Overall, 40% of prescribing issues could have deleterious consequences. Prescribing issues occurred mainly with non-HIV drugs and included: incorrect dosage (26%); lack of indication (21%); prescription omission (drug not prescribed although indicated) (17%); drug not appropriate in elderly individuals (18%) and deleterious DDIs (17%). In the multivariable logistic regression, risk factors for prescribing issues were polypharmacy (OR: 2.5; 95% CI: 1.3–4.7), renal impairment (OR: 2.7; 95% CI: 1.4–5.1), treatment with CNS-active drugs (OR: 2.1; 95% CI: 1.1–3.8) and female sex (OR: 8.3; 95% CI: 2.4–28.1).

In conclusion, prescribing issues are common in elderly people living with HIV, consistent with reports in uninfected elderly individuals. Inappropriate prescribing represents a risk for the patient, although it should be noted that it does not necessarily lead to harm. Medication reconciliation and periodic review prescriptions by experienced physicians, ideally as part of multidisciplinary consultations, could reduce the risk of inappropriate prescribing. However, in clinical practice, this approach can be difficult to implement due to the pressure from hospitals and healthcare systems to reduce consultation times. Finally, the study shows that female individuals are at higher risk of inappropriate prescribing, thus doctors should be careful to avoid bias and attention is needed when prescribing for women.


10th February Dietrich et al., Kidney dysfunction and HIV

Rapid progression of Kidney dysfunction in Swiss people living with HIV: Contribution of polygenic risk score and D:A:D clinical risk score.    Journal of Infectious Diseases

Dietrich et al. aimed to assess and quantify the contribution of genetic background, D:A:D chronic kidney disease (CKD) risk score, and relevant antiretroviral therapy (ART) exposures to rapid progression of kidney dysfunction.

They obtained univariable and multivariable hazard ratios (HR) for rapid progression, based on the clinical D:A:D CKD risk score, antiretroviral exposures, and a polygenic risk score based on 14’769 genome-wide single nucleotide polymorphisms in white Swiss HIV Cohort Study participants. For the non-genetic risk factors, only variables included in the CKD risk score (mode of HIV transmission, hepatitis C coinfection, age, baseline eGFR, sex, CD4 nadir, hypertension, prior cardiovascular disease, and diabetes mellitus) were included.

The study included 225 participants with rapid progression and 3’378 rapid progression-free participants. In multivariable analysis, compared to participants with low D:A:D risk, participants with high risk had rapid progression (HR = 1.82 [95% CI, 1.28–2.60]). Compared to the first (favorable) polygenic risk score quartile, participants in the second, third, and fourth (unfavorable) quartiles had rapid progression (HR = 1.39 [95% CI, 0.94–2.06], 1.52 [95% CI, 1.04–2.24], and 2.04 [95% CI, 1.41–2.94], respectively). Recent exposure to tenofovir disoproxil fumarate was associated with rapid progression (HR = 1.36 [95% CI, 1.06–1.76]).

In conclusion, some people living with HIV experience rapidly deteriorating kidney dysfunction and these analyses reveal an independent contribution of an individual polygenic risk score to explaining interindividual variation in rapid progression. The study extends the our previous observation that genetic background associates with CKD risk and highlight the importance of longitudinal study design to quantify the effect size of polygenic risk score on rapid progression, in the context of multiple shifting environmental risk factors, most notably clinical D:A:D CKD risk score and potentially nephrotoxic antiretroviral exposures.


27th January Gryaznov et al., Smartphone app and CO self-monitoring support for smoking cessation

Smartphone app and carbon monoxide self-monitoring support for smoking cessation: A randomised controlled trial nested into the Swiss HIV Cohort Study.   JAIDS

Gryaznov et al. investigated whether exhaled carbon monoxide (CO) self-monitoring in conjunction with a smoking cessation app may improve smoking cessation in HIV-positive smokers.

They nested a randomized controlled into the Swiss HIV Cohort Study and randomly allocated during biannual cohort visits patients smoking ≥3 cigarettes a day via a trial website to counselling by SHCS center physicians (usual care) or to a combined intervention of CO self-monitoring with mobile phone-based feedback and app-based smoking cessation support.

At the start of the trial on June 1, 2017, 3’293 of 10’493 (34%) patients in the SHCS smoked ≥3 cigarettes and these 2’444 (74%) indicated at any cohort visit in the previous 48 months to have quit once and then resumed smoking. During a recruitment period of 1.5 years, 1’807 patients were screened for inclusion and a total of 81 patients were enrolled. Six of 42 (14%) participants in the intervention group and 5 of 39 (13%) in the standard of care group quit smoking at 6 months follow-up (adjusted odds ratio 1.06, 95% CI: 0.29 to +3.86) and 3 participant were lost to follow-up. Based on the 12-month cohort data, one individual had resumed smoking and 5 trial participants reported to have quit smoking. The adjusted mean difference in smoked cigarettes between the intervention and control groups at 6 months was −1.38 (95% CI: −4.45 to 1.69).

In conclusion, results from this pragmatic trial remained inconclusive and underpowered because of recruitment difficulties, although the nested trial design allowed for the potential to recruit from a large group of smokers with a self-reported history for quitting. Patients included in the trial reported more cessation attempts which was identified as the best predictor for successful quitting from observational data analysis of the SHCS. This information, however, did not translate into a high recruitment rate. Overall, 11% of the trial population - irrespective of the intervention - quit, which is considerably higher than the 1.6% smokers in the remaining cohort who had indicated to have quit.


20th January Reichmuth et al., HIV-1 transmission drivers

Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission.   HIV Medicine

Reichmuth et al. aimed to develop and to test a molecular epidemiology method based on phylogeny reconstruction and cluster analysis to characterize potential HIV-1 transmitters and understand the drivers of the HIV-1 epidemic in Switzerland. This method was developed and validated using longitudinally sampled HIV-1 partial polymerase (pol) nucleotide sequences, routinely and retrospectively obtained, in the drug resistance database (DRDB) of the Swiss HIV Cohort Study (SHCS).

The proposed method was able to identify 279 potential HIV-1 transmitters and allowed the authors to determine the main epidemiological and virological drivers of transmission. They found that the directionality of transmission was consistent with infection times for 72.9% of 85 potential HIV-1 transmissions with accurate infection date estimates. Being a potential HIV-1 transmitter was associated with risk factors including viral load [adjusted odds ratiomultivariable (95% confidence interval): 1.86 (1.49–2.32)], syphilis coinfection [1.52 (1.06–2.19)], and recreational drug use [1.45 (1.06–1.98)]. By contrast for the potential HIV-1 recipients, this association was weaker or even absent [1.18 (0.82–1.72), 0.89 (0.52 –1.55) and 1.53 (0.98–2.39), respectively], indicating that inferred directionality of transmission is useful at the population level.

In conclusion, identifying drivers of HIV-1 transmission by not only identifying transmission clusters but also characterizing individuals who may have potentially transmitted HIV-1 is of great importance for understanding the drivers of the HIV-1 epidemic. The associated risk factors at an individual level are crucial to better understanding the dynamics and mechanisms of an HIV-1 epidemic and will help to tackle the various ongoing epidemics at the population level, but in a more individualized manner. The proposed method was validated using the densely sampled setting of the SHCS as a case study. This lays the groundwork to study evolution and transmission of HIV-1, as well as the risk factors of HIV-1 transmitters, and allows large transmission clusters to be characterized.


13th January Mocroft et al., Outcomes in antiretroviral-naïve adults

Treatment outcomes of integrase inhibitors, boosted protease inhibitors and non-nucleoside reverse transcriptase inhibitors in antiretroviral naïve persons starting treatment.   HIV Medicine

Mocroft et al. on behalf of the RESPOND study-group aimed to compare shorter term virological and immunological outcomes and clinical events of AIDS/death in ART-naïve persons starting antiretroviral therapy (ART) in RESPOND with either an integrase strand transfer inhibitor (INSTI), contemporary boosted protease inhibitors (PI/b) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) in key subgroups.

The International Cohort Consortium of Infectious Diseases (RESPOND) is a collaboration of 17 cohort studies, including 29’432 HIV-1-positive persons from across Europe and Australia. The composite treatment outcome (cTO) defined success as viral load (VL) <200 HIV-1 RNA copies/mL with no regimen change and no AIDS/death events. Immunological success was defined as a CD4 count >750 cells/lL or a 33% increase where the baseline CD4 count was ≥500 cells/lL.

Of 5’198 ART-naıve persons in RESPOND, 45.4% started INSTIs, 26.0% PI/b and 28.7% NNRTIs; 880 (17.4%) were aged >50 years, 2539 (49.4%) had CD4 counts <350 cells/lL and 1891 (36.8%) had VL >100 000 copies/mL. Differences in virological and immunological success and clinical failure among ART classes were similar across age groups (≤40, 40 –50 and >50 years), CD4 count categories (≤350 vs. >350 cells/lL) and VL categories at ART initiation (≤100 000 vs. >100 000 copies/mL), with all investigated interactions being nonsignificant (P >0.05).

In conclusion, differences among ART classes in virological, immunological and clinical outcomes in ART-naïve participants were consistent irrespective of age, immune suppression or VL at ART initiation. While confounding by indication cannot be excluded, this provides reassuring evidence that such subpopulations will equally benefit from modern ART.


6th January Kusejko et al., The interplay of HIV and latent tuberculosis

Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV.     PLoS Biology

Kusejko et al. aimed to investigate the association of Mycobacterium tuberculosis (MTB) status with HIV disease progression, including both the HIV set point viral load (SPVL) and the occurrence of opportunistic infections (OIs).

The authors sorted all participants of the Swiss HIV Cohort Study (SHCS) with at least 1 documented MTB test into one of the 3 groups: MTB uninfected, latent TB infection (LTBI), or active TB. In adjusted models, they corrected for baseline demographic characteristics, i.e., HIV transmission risk group and gender, geographic region, year of HIV diagnosis, and CD4 nadir.

A total of 13’943 SHCS patients had at least 1 MTB test documented, of whom 840 (6.0%) had LTBI and 770 (5.5%) developed active TB. Compared to MTB uninfected patients, LTBI was associated with a 0.24 decreased log HIV SPVL in the adjusted model (p < 0.0001). Patients with LTBI had lower odds of having candida stomatitis (adjusted odds ratio (OR) = 0.68, p = 0.0035) and oral hairy leukoplakia (adjusted OR = 0.67, p = 0.033) when compared to MTB uninfected patients.

In conclusion, the study demonstrated that LTBI was associated with a reduced HIV SPVL and fewer cases of the most prevalent OIs on a population level. These associations were robust to adjusting for the most important demographic and clinical confounders. Independently, various sensitivity analyses further strengthened these observations. These findings support the hypothesis that LTBI can benefit host immune responses and provides new avenues for future research to continue to unravel the complex interactions between mycobacteria and humans.